Back to Results
First PageMeta Content
Hepatology / Clinical research / Brain disorders / Bioethics / Rifaximin / Lactulose / Irritable bowel syndrome / Hepatic encephalopathy / Placebo / Medicine / Health / Pharmacology


Document Date: 2014-10-01 21:56:22

Open Document

File Size: 100,33 KB

Share Result on Facebook

City

Trial / /

Company

USA Agency for Healthcare Research / Norgine Pty Ltd / New England Journal / Philips / PBAC / /

Country

Australia / /

Currency

USD / /

Event

Product Recall / FDA Phase / Product Issues / /

IndustryTerm

rifaximin / study protocol / treatment of irritable bowel syndrome / comparator / proposed managed entry scheme study protocol / prospective trial protocol / /

MedicalCondition

A. et al Chronic / reversible neuropsychiatric disorder / disease / coma / cirrhosis / hepatic encephalopathy / hepatic encephalopathy patients / fulminant hepatic failure / portal hypertension / overt hepatic encephalopathy / chronic liver failure / delirium / asterixis / End-Stage Liver Disease / irritable bowel syndrome / hepatic insufficiency / /

Organization

USA Agency for Healthcare Research and Quality / Antimicrobial Resistance Subcommittee / /

Position

driver / Publication title author / /

Product

Rifaximin / previous acceptance / Xifaxan / lactulose / previous concern / PBAC / RFHE3001 / sponsor / /

ProvinceOrState

Connecticut / /

PublishedMedium

New England Journal of Medicine / /

Region

New England / /

Technology

study protocol / detailed prospective trial protocol / proposed managed entry scheme study protocol / /

URL

http /

SocialTag